Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Operating Leases (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Operating Leases for 5 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 68.2% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2025, down 68.2%, and an annual FY2025 reading of $1.5 million, down 68.2% over the prior year.
  • Operating Leases was $1.5 million for Q4 2025 at Aligos Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $11.3 million in Q4 2021 and bottomed at $1.5 million in Q4 2025.
  • Average Operating Leases over 5 years is $7.5 million, with a median of $8.5 million recorded in 2023.
  • The sharpest move saw Operating Leases increased 6.56% in 2022, then crashed 68.2% in 2025.
  • Year by year, Operating Leases stood at $11.3 million in 2021, then fell by 18.48% to $9.2 million in 2022, then fell by 16.66% to $7.7 million in 2023, then plummeted by 37.47% to $4.8 million in 2024, then plummeted by 68.2% to $1.5 million in 2025.
  • Business Quant data shows Operating Leases for ALGS at $1.5 million in Q4 2025, $2.4 million in Q3 2025, and $3.2 million in Q2 2025.